Clinical Trial Update: A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ametumumab with anti-PD-1 antibody and FOLFIRI in RAS wild-type advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Ametumumab (ametumumab)
• Anti-PD-1 Monoclonal Antibody
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Shanghai Celfuture Biotech Co., Ltd. | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN